PAM483

ARN de interferencia pequeños y otros medicamentos constituidos por ácidos nucleicos

REVISIÓN

Lüdtke FL, Silva TJ, da Silva MG, Hashimoto JC, Ribeiro APB. Lipid Nanoparticles: Formu lation, Production Methods and Characterization Protocols. Foods. 2025; 14(6): 973. DOI: 10.3390/ foods14060973 . Luther DC, Huang R, Jeon T, Zhang X, Lee YW, Nagaraj H et al . Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles. Adv Drug Deliv Rev. 2020; 156: 188-213. DOI: 10.1016/j.addr.2020.06.020 . Marwick C. First “antisense” drug will treat CMV retinitis. JAMA. 1998 Sep 9; 280(10): 871. Mascini M, Palchetti I, Tombelli S. Nucleic acid and peptide aptamers: fundamentals and bioa nalytical aspects. Angew Chem Int Ed Engl. 2012; 51(6): 1316-32. DOI: 10.1002/anie.201006630 . Plescia OJ, Palczuk NC, Cora-Figueroa E, Mukherjee A, Braun W. Production of antibodies to soluble RNA (sRNA). Proc Natl Acad Sci U S A. 1965; 54(4): 1281-5. DOI: 10.1073/ pnas.54.4.1281 . Ramírez Vaca E. Las amiloidosis y su tratamiento. Panorama Actual Med. 2024; 48(477): 1042 1063. Saha S, Tandon R, Sanku J, Kumari A, Shukla R, Srivastava N. siRNA-based Therapeutics in Hormone-driven Cancers: Advancements and benefits over conventional treatments. Int J Pharm. 2025; 674: 125463. DOI: 10.1016/j. ijpharm.2025.125463 . Tao R, Han X, Bai X, Yu J, Ma Y, Chen W et al .

Oligonucleotides for Enhanced Gene Inhibition in Mammalian Cells. Methods Mol Biol. 2021; 2282: 119-36. DOI: 10.1007/978-1-0716-1298-9_8 . Singh SK, Agrawal P et al . Next-Gen Cancer Treatment: Nanotechnology-Driven siRNA Deli very Solutions. Assay Drug Dev Technol. 2025. DOI: 10.1089/adt.2024.121 . zowski L, Saluk-Bijak J, Bijak M. Various Aspects of a Gene Editing System-CRISPR-Cas9. Int J Mol Sci. 2020; 21(24): 9604. DOI: 10.3390/ ijms21249604 . Jansson-Löfmark R, Gennemark P. Inferring Half-Lives at the Effect Site of Oligonucleotide Drugs. Nucleic Acid Ther. 2018 Dec; 28(6): 319 325. DOI: 10.1089/nat.2018.0739 . Kumthekar P, Ko CH, Paunesku T, Dixit K, So nabend AM, Bloch O et al . A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. Sci Transl Med. 2021; 13(584): eabb3945. DOI: 10.1126/scitranslmed.abb3945 . Liu M, Wang Y, Zhang Y, Hu D, Tang L, Zhou B et al . Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines. Signal Transduct Target Ther. 2025b; 10(1): 73. DOI: 10.1038/ s41392-024-02112-8 . Liu Y, Wang C, Fu X, Ren M. The Progress and Evolving Trends in Nucleic-Acid-Based Therapies. Biomolecules. 2025a; 15: 376. DOI: 10.3390/ biom15030376 . Harshita, Harish V, Upendra SL, Mohd S, Janik E, Niemcewicz M, Ceremuga M, Kr

editing technology. Front Immunol. 2024; 15: 1354825. DOI: 10.3389/fimmu.2024.1354825 . Tripathy RK, Pande AH. Nanobody-Oligonucleotide Conjugates (NucleoBodies): The Next Frontier in Oligonucleotide Therapy. Pharm Res. 2025; 42(2): 219-236. DOI: 10.1007/s11095-025-03829-z . Weiskirchen R, Weiskirchen S, Grassi C, Scaggiante B, Grassi M, Tierno D et al . Recent advances in optimizing siRNA delivery to hepatocellular carcinoma cells. Expert Opin Drug Deliv. 2025; 1–17. DOI: 10.1080/17425247.2025.2484287 . Zhang Y, Liu H, Zhen W, Jiang T, Cui J. Advan cement of drugs conjugated with GalNAc in the targeted delivery to hepatocytes based on asialo glycoprotein receptor. Carbohydr Res. 2025; 552: 109426. DOI: 10.1016/j.carres.2025.109426 . Zhang Y, Liu Q, Zhang X, Huang H, Tang S, Chai Y et al . Recent advances in exosome-me diated nucleic acid delivery for cancer therapy. J Nanobiotechnology. 2022; 20(1): 279. DOI: 10.1186/s12951-022-01472-z

Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene

467